GBT Announces New Employment Inducement Grants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
RBC Capital Steps Aside on Global Blood Therapeutics (GBT), 'Oxbryta Beat Confirms Value; With Solid Outcome'
August 8, 2022 4:19 PM EDTRBC Capital analyst Gregory Renza downgraded Global Blood Therapeutics (NASDAQ: GBT) from Outperform to Sector Perform with a price target of $68.50 (from $60.00).
The analyst comments "Srong Oxbryta revenue beat for 2Q22 and the PFE acquisition underscore the strong fundamentals... More
